Literature DB >> 6254073

Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

D A Thorley-Lawson, K Geilinger.   

Abstract

Hybridomas producing antibodies against Epstein-Barr virus (EBV) have been produced. They have been screened for production of antibodies against the EBV-associated membrane antigens that are present on EBV producer cell lines. For the screening test we used a double-antibody radioimmunoassay with 125I-labeled rabbit anti-mouse Ig as the second step. Positive cultures were cloned and one such clone, C1, was used for further study. C1 antibody neutralizes EBV in vitro and immunoprecipitates both gp350 (the major glycoprotein in B95-8 cells) and gp220 (the major glycoprotein in P3HR-1 cells) from the membrane antigen complex, suggesting that these molecules are antigenically related. The presence of gp350/220 both on the plasma membrane and in the cytoplasm may be detected by immunofluorescence with C1 antibody.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254073      PMCID: PMC350047          DOI: 10.1073/pnas.77.9.5307

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with Epstein-Barr virus.

Authors:  A Svedmyr; A Demissie; G Klein; P Clifford
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

2.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

3.  Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy.

Authors:  H zur Hausen; W Henle; K Hummeler; V Diehl; G Henle
Journal:  J Virol       Date:  1967-08       Impact factor: 5.103

4.  The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

5.  Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells.

Authors:  W Henle; K Hummeler; G Henle
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

6.  Studies of 125I trace labeling of immunoglobulin G by chloramine-T.

Authors:  S Sonoda; M Schlamowitz
Journal:  Immunochemistry       Date:  1970-11

7.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

Authors:  G Henle; W Henle; V Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

8.  Virus in cultured lymphoblasts from a New Guinea Burkitt lymphoma.

Authors:  M A Epstein; B G Achong; J H Pope
Journal:  Br Med J       Date:  1967-04-29

9.  Chemical coupling of proteins to agarose.

Authors:  J Porath; R Axen; S Ernback
Journal:  Nature       Date:  1967-09-30       Impact factor: 49.962

10.  Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.

Authors:  T Shope; D Dechairo; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

View more
  84 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Authors:  Susan M Turk; Ru Jiang; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 4.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

Review 6.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

7.  Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication.

Authors:  Li Xing; Elliott Kieff
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

Review 9.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

10.  Identification and characterization of murine gammaherpesvirus 68 gp150: a virion membrane glycoprotein.

Authors:  J P Stewart; N J Janjua; S D Pepper; G Bennion; M Mackett; T Allen; A A Nash; J R Arrand
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.